Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
Yahoo FinanceApr 30 10:00 ET
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)
TipRanksApr 29 21:41 ET
Those Who Invested in Vertex Pharmaceuticals (NASDAQ:VRTX) Five Years Ago Are up 127%
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shareholders might be concerned after seeing the share price drop 11% in the last quarter. But in stark contrast, the returns over the last half de
Simply Wall StApr 29 12:24 ET
How Is The Market Feeling About Agilent Technologies?
Agilent Technologies's (NYSE:A) short percent of float has risen 10.14% since its last report. The company recently reported that it has 3.95 million shares sold short, which is 1.52% of all regular s
BenzingaApr 29 10:45 ET
Agilent Names Simon May to Lead Diagnostics and Genomics Group
Agilent Technologies, Inc. (NYSE:A) today announced Simon May has been named president of the company's Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science
BusinesswireApr 29 08:45 ET
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow JonesApr 29 07:45 ET
Express News | Intellia Therapeutics Announced The Acceptance Of An Oral Presentation From The Phase 1 Portion Of The Ongoing NTLA-2002 Phase 1/2 Study At The European Academy Of Allergy And Clinical Immunology Congress 2024
BenzingaApr 29 07:31 ET
Express News | Apellis Pharmaceuticals Inc : Mizuho Cuts Target Price to $52 From $60
ReutersApr 29 06:40 ET
J&J, Roche, AstraZeneca Poised to Have Highest Orphan Drug Sales by End of Decade
Seeking AlphaApr 28 13:00 ET
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
Yahoo FinanceApr 26 17:50 ET
EDIT, CLNE and NIU Are Among After Hour Movers
Seeking AlphaApr 26 17:00 ET
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
TipRanksApr 26 16:23 ET
Express News | Bluebird bio Announces Receipt of Expected Notice From Nasdaq
ReutersApr 26 16:05 ET
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc's (NASDAQ:VRTX) blockbuster drug Trikafta for cystic fibrosis (CF) has shown remarkable efficacy, potentially extending the lives of some patients by up to 45 years. Despite
BenzingaApr 26 14:34 ET
Express News | HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
BenzingaApr 26 14:22 ET
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
TipRanksApr 26 11:45 ET
Express News | Vertex Announces European Commission Approval for Kalydeco® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
ReutersApr 26 11:43 ET
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Pharmaceuticals (APLS) said Friday that the review of the marketing authorization application for pegcetacoplan has been reset to day 180, the last phase of the initial assessment by the Europ
MT NewswiresApr 26 10:30 ET
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Yahoo FinanceApr 26 08:25 ET
Declining Stock and Solid Fundamentals: Is The Market Wrong About Agilent Technologies, Inc. (NYSE:A)?
Yahoo FinanceApr 26 08:00 ET